Syndax Pharmaceuticals Inc has a consensus price target of $33.86, established from looking at the 44 latest analyst ratings. The last 3 analyst ratings were released from Citigroup, Stifel, and HC Wainwright & Co. on May 9, 2024. With an average price target of $37 between Citigroup, Stifel, and HC Wainwright & Co., there's an implied 70.82% upside for Syndax Pharmaceuticals Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|
The latest price target for Syndax Pharmaceuticals (NASDAQ: SNDX) was reported by Citigroup on May 9, 2024. The analyst firm set a price target for $30.00 expecting SNDX to rise to within 12 months (a possible 38.50% upside). 27 analyst firms have reported ratings in the last year.
The latest analyst rating for Syndax Pharmaceuticals (NASDAQ: SNDX) was provided by Citigroup, and Syndax Pharmaceuticals maintained their buy rating.
There is no last upgrade for Syndax Pharmaceuticals.
The last downgrade for Syndax Pharmaceuticals Inc happened on January 31, 2024 when Scotiabank changed their price target from $36 to $23 for Syndax Pharmaceuticals Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Syndax Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Syndax Pharmaceuticals was filed on May 9, 2024 so you should expect the next rating to be made available sometime around May 9, 2025.
While ratings are subjective and will change, the latest Syndax Pharmaceuticals (SNDX) rating was a maintained with a price target of $32.00 to $30.00. The current price Syndax Pharmaceuticals (SNDX) is trading at is $21.66, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.